Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children's oncology group pilot study

Journal of Clinical Oncology

Volumn 26, Issue 22, 2008, Pages 3756-3762

  Raetz, Elizabeth A ^a   Cairo, Mitchell S ^a   Borowitz, Michael J ^a   Blaney, Susan M ^a   Krailo, Mark D ^a   Leil, Tarek A ^a   Reid, Joel M ^a   Goldenberg, David M ^a   Wegener, William A ^a   Carroll, William L ^a   Adamson, Peter C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD22 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; METHOTREXATE; PARACETAMOL; PETHIDINE; PREDNISONE; RAZOXANE; VINCRISTINE; ANTINEOPLASTIC AGENT; CD22 PROTEIN, HUMAN; HLL2 AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL; MALE; MINIMAL RESIDUAL DISEASE; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RIGOR; TREATMENT RESPONSE; BLOOD; BONE MARROW; DRUG ADMINISTRATION; DRUG EFFECT; FEASIBILITY STUDY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHATIC LEUKEMIA; PILOT STUDY; PRESCHOOL CHILD; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD22; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TREATMENT OUTCOME;

EID: 49249109608     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3528     Document Type: Article

References (35)

1. Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al: Pathways through relapses and deaths of children with acute lymphoblastic leukemia: Role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol 24:5750-5762, 2006
2. Einsiedel HG, von Stackelberg A, Hartmann R, et al: Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 23:7942-7950, 2005
3. Gaynon PS, Harris RE, Altman AJ, et al: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. J Clin Oncol 24:3150-3156, 2006
4. Rivera GK, Zhou Y, Hancock ML, et al: Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 103:368-376, 2005
5. Coustan-Smith E, Gajjar A, Hijiya N, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 18:499-504, 2004
6. Eckert C, Biondi A, Seeger K, et al: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358:1239-1241, 2001
7. Shih LB, Lu HH, Xuan H, et al: Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56:538-545, 1994
8. Carnahan J, Wang P, Kendall R, et al: Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res 9:3982S-90S, 2003
9. Carnahan J, Stein R, Qu Z, et al: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44:1331-1341, 2007
10. Leonard JP, Coleman M, Ketas J, et al: Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 23:5044-5051, 2005
11. Leonard JP, Coleman M, Ketas JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003
12. Leonard JP, Coleman M, Ketas JC, et al: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004
13. Strauss SJ, Morschhauser F, Rech J, et al: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 24:3880-3886, 2006
14. Micallef IN, Kahl BS, Maurer MJ, et al: A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer 107:2826-2832, 2006
15. Steinfeld SD, Tant L, Burmester GR, et al: Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: An open-label phase I/II study. Arthritis Res Ther 8:R129, 2006
16. Dörner T, Kaufmann J, Wegener WA, et al: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74, 2006
17. Goldenberg DM: Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 6:1341-1353, 2006
18. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
19. Borowitz MJ, Pullen DJ, Shuster JJ, et al: Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: Relation to other risk factors - A Children's Oncology Group study. Leukemia 17:1566-1572, 2003
20. Anderson BD, Adamson PC, Weiner SL, et al: Tissue collection for correlative studies in childhood cancer clinical trials: Ethical considerations and special imperatives. J Clin Oncol 22:4846-4850, 2004
21. Stein R, Belisle E, Hansen HJ, et al: Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 37:293-298, 1993
22. Tedder TF, Tuscano J, Sato S, et al: CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 15:481-504, 1997
23. Gaynon PS: Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 131:579-587, 2005
24. Chessells JM, Veys P, Kempski H, et al: Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123:396-405, 2003
25. Gaynon PS, Qu RP, Chappell RJ, et al: Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse - The Children's Cancer Group Experience. Cancer 82:1387-1395, 1998
26. Roy A, Cargill A, Love S, et al: Outcome after first relapse in childhood acute lymphoblastic leukaemia: Lessons from the United Kingdom R2 trial. Br J Haematol 130:67-75, 2005
27. Raetz EA, Borowitz MJ, Devidas M, et al: A re-induction platform for children with first marrow relapse of acute lymphoblastic leukemia: Results from Children's Oncology Group study AALL01P2. J Clin Oncol (in press)
28. Buchanan GR, Rivera GK, Boyett JM, et al: Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: A Pediatric Oncology Group Study. Blood 72:1286-1292, 1988
29. Feig SA, Ames MM, Sather HN, et al: Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from the Children's Cancer Group. Med Pediatr Oncol 27:505-514, 1996
30. Sadowitz PD, Smith SD, Shuster J, et al: Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 81:602-609, 1993
31. Testi AM, Del Giudice I, Arcese W, et al: A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: A study of the AIEOP group. Br J Haematol 118:741-747, 2002
32. Crooks GM, Sato JK: Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 17:34-38, 1995
33. Kolb EA, Steinherz PG: A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia 17:1967-1972, 2003
34. Wells RJ, Feusner J, Devney R, et al: Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol 3:998-1004, 1985
35. Leonard JP, Goldenberg DM: Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26:3704-3713, 2007